Peter Kolchinsky and The Great American Drug Deal

Biopharmaceutical innovation requires a hefty investment: A recent study published in The Journal of the American Medical Association (JAMA) reported an average cost of $1.3 billion to bring a new drug to market, from drug discovery through clinical trials to approval. And it is often the biopharma company that comes under fire when cost burden to patients is in question. But affordability of these innovations is not the biopharma industry’s cross to bear alone, according to Peter ...